+1 Recommend
2 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Novel Clinical and Genomic Signatures of the 2022 Monkeypox Virus

      1 , # , 1 , # , 1 , 2 , * ,
      monkeypox, outbreak, evolution, treatment, prevention


            The monkeypox outbreaks started in 2022 and became an unexpected public health emergency of international concern (PHEIC). The factors that drove this neglected zoonosis in Africa into a global focus is largely unknown. Combined clinical, epidemiologic, and phylogenomic analyses indicate that substantial genome mutations, deletions, and rearrangement contributed to the sudden outbreak and unusual features in transmission and outcomes. Because no vaccine or antiviral drug is available in China, we call for immediate action and collaboration in response to the new monkeypox crisis.

            Main article text


            Monkeypox (MPX) is a typical zoonosis that is caused by the monkeypox virus (MPXV) of the Orthopoxvirus genus, which includes the well-known smallpox, vaccinia, and cowpox viruses. Similar to smallpox virus, MPXV infection has a clinical onset with fevers, myalgias, fatigue, and headaches, which are frequently followed by skin lesions with pustular papules and ulcerations [1]. Generally, lymphadenopathy differentiates MPXV infections from smallpox virus infections. MPXV was initially identified and endemic in Central and West Africa countries, where the natural hosts are rodents and non-human primates [2,3]. For decades, human MPX cases were mostly restricted to zoonotic infections with limited human-to-human spread. Since the first confirmed MPX case on 7 May 2022 in the United Kingdom [4], >78,000 confirmed cases have been reported in more than 110 countries, including China, as of 8 November 2022 (WHO). The Food and Drug Administration (FDA) has approved two vaccines and three antiviral drugs to prevent and treat MPX, none of which are available in China.

            The sudden increase in number of MPX cases and geographic expansion were accompanied by some unusual clinical outcomes and transmission routes. The number of MPX infections rapidly increased, suggesting a more effective human-to-human transmission than previously recorded. The case-fatality rate (0.025%) of the current outbreak, however, is much lower than classic MPX (1%-15%) prior to 2022 [1]. Notably, the majority of the reported cases are identified in men who have sex with men (MSM), and the rapid spread of MPX in MSM has been attributed to sexual promiscuity of affected individuals [5]. Contact with infectious viral material from skin lesions occurring during sexual intercourse has been identified as the main risk factor [6,7]. Additionally, during the present outbreak, some MPX patients had asymptomatic infections or milder symptoms with fewer skin lesions, implying the current MPXV was cryptically transmitted in populations for a long time [8]. In addition, other changes might be responsible for the novel features of this epidemic.


            Viral adaptive mutations have been reported to contribute to the initiation of the pandemic, as well as enhanced phenotypes in pathogenicity and transmissibility [9,10]. Direct comparison of historical and contemporary MPXV strain genomes are hoped to provide clues to these unanswered questions. The MPXV genome consists of a large double-stranded DNA, encoding approximately 190 genes. Before the 2022 outbreak, MPXV was classified into two clades: the Congo Basin Clade (clade 1), which is predominant in Central Africa with severe symptoms and a higher mortality rate (>10%), and clade 2, which circulates in West Africa with milder cases and a lower mortality rate (1%-3%). The rapid transmission of MPXV might be related to the genomic divergence from these two clades. Recently, Gomes and colleagues [11] analyzed the phylogenomic characterization of the first viral genome sequences of the 2022 MPXV outbreak. Gomes et al. [11] suggested that the current outbreak clustered with 2018–2019 cases (clade 2) linked to an endemic country, indicating that the current global outbreak originated from a single epidemic region. The current lineage, however, is segregated to a different phylogenetic branch (B.1) with approximately 50 genetic differences in the recent epidemic MPXV genomes. It is concerning that the substitution rate of current MPXV was far more than that previously estimated for orthopoxviruses, and most of the nucleotide substitutions involved conserved features with GA>AA and TC>TT nucleotide replacements [12]. Another study reported similar mutation features in the 2022 MPX cases in the United States [13]. This mutational bias might be associated with the apolipoprotein B mRNA-editing catalytic polypeptide-like 3 (APOBEC3) enzyme, a DNA cytidine deaminase, which inhibits viral replication by editing the viral genome mutations (Figure 1). The excess of 2022 MPXV mutations indicates an accelerated adaptive evolution derived by host APOBEC3. This finding highlights the need of further functional studies to determine whether these mutations contribute to the enhanced transmissibility of the virus or facilitate viral evasion of host immunity.

            FIGURE 1 |

            Viral adaptive evolution may be responsible for the new clinical and epidemiologic features of the monkeypox (MPX) outbreak in 2022. Prior to 2022, MPX was a rare zoonosis with limited human-to-human transmission in Central and West Africa. The current MPX outbreak has spread to more than 110 countries with greater than 78,000 confirmed cases. Epidemiologic and phylogenomic analyses indicate that the current MPX outbreak might originate from epidemic regions. Additionally, APOBEC3-derived mutations, as well as viral genomic rearrangement, may lead to viral adaptive evolution which could account for the new clinical-epidemiologic features of the current MPX.


            In addition to single nucleotide polymorphisms (SNPs), insertions, deletions, and genome rearrangements are commonly detected in the poxvirus genome terminal, which may be associated with altered infectivity and pathogenicity. It has been reported that genome end-region rearrangements have an important role in the virulence and evolution of smallpox virus [14,15]. Genomic rearrangements have also been detected in the current outbreak MPXV. A recent study by Li and colleagues [16] identified a large genomic deletion and rearrangement in MPXV sequences from MSM cases in the United States, where the largest number of cases have been reported. Li et al. [16] found large-scale genomic changes, ranging from 2.3-15kb, involved in several protein coding sequences (CDS) and inverted terminal repeat (ITR) terminal regions. Deletion of the gene encoding a surface glycoprotein (B21L) and zinc finger-like protein (D5R), as well as a truncated ITR, are thought to be involved in immunomodulation, virulence, and the poxvirus host range [14,17]; however, it is too early to determine if these large genomic changes are beneficial, neutral, or harmful to MPXV transmission and pathogenicity. The authors also found a genomic deletion of one sample involved in the target gene of clade II MPXV-specific PCR assays. The large-scale genomic deletion might eventually render the PCR assay ineffective, and PCR assays targeting the terminal regions may be most at risk. Consequently, PCR assays targeting the conserved region or targeting multiple different regions may be necessary to ensure the identification of viruses harboring large deletions. Overall, the emergence of genomic rearrangements highlights the continued need for genomic surveillance of MPXV to study viral evolution during the current epidemic.

            In recent decades, refinement of genetic engineering methods based on vaccinia virus have contributed to facilitate the reverse genetic manipulation of poxvirus genomes [18]. Using standard recombination technology, researchers have found that loss of D14L is not the sole virulence factor responsible for the different pathogenicity between MPXV clades 1 and 2 [19]. The observed rapid mutations and large-scale genomic rearrangements in the MPXV genome raise concern that the contemporary circulating strains might be undergoing accelerated evolution with unusual clinical outcomes. Ongoing investigation with reverse genetics will help clarify this issue. More importantly, extensive molecular surveillance and epidemiology investigations are warranted to identify novel mutations that are potentially related to viral transmission, pathogenicity, and escape from available countermeasures.


            The two treatments that are currently authorized for MPX (tecovirimat and brincidofovir) inhibit the viral envelop protein, p37, and block viral DNA polymerase, respectively [20]. Several compounds, such as adamantane derivatives, NIOCH-14, PAV-886, mitoxantrone and ribavirin, have been reported to be effective against orthopoxviruses in vitro by blocking p37 formation, viral DNA and protein synthesis, and viral release and entry [2123]. These compounds enhance the availability and spectrum of the effective antiviral drug against poxviruses; however, the efficacy and safety against the current emerging MPX are largely unknown and require further preliminary and clinical research. As all approved vaccines and antivirals are originally designed to prevent smallpox, whether the vaccines could efficiently prevent the current MPX remains unknown. According to a recent study, vaccination with 2-shot MVA-BN, a third-generation attenuated smallpox vaccine approved for use as a vaccine against MPX, yield relatively low levels of neutralizing antibodies to the epidemic MPXV strain, indicating the need to develop vaccines tailored to prevent current MPXV [24]. Innovative vaccine platforms, like mRNA vaccines, have exhibited excellent protection efficacy and great application prospects during the COVID-19 pandemic, which will facilitate the development of MPX vaccines. To thwart continuation of the current MPX epidemic, it is important to raise awareness and build diagnostic capacity for populations, especially at-risk groups. Additionally, the stigma and discrimination within the MSM community must be eliminated, and equal access to diagnosis, treatment, and vaccines must be provided. Finally, we should initiate global collaborations to evaluate the effectiveness of current treatments, vaccines, and vaccination strategies.


            The authors declare no competing interests.


            1. Gessain A, Nakoune E, Yazdanpanah Y. Monkeypox. N Engl J Med. 2022. Vol. 387:1783–1793

            2. Beer EM, Rao VB. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Negl Trop Dis. 2019. Vol. 13(10):e0007791

            3. Arita I, Henderson DA. Smallpox and monkeypox in non-human primates. Bull World Health Organ. 1968. Vol. 39(2):277–283

            4. Vivancos R, Anderson C, Blomquist P, Balasegaram S, Bell A, Bishop L, et al.. Community transmission of monkeypox in the United Kingdom, April to May 2022. Euro Surveill. 2022. Vol. 27(22):2200422

            5. Kupferschmidt K. Why monkeypox is mostly hitting men who have sex with men. Science. 2022. Vol. 376(6600):1364–1365

            6. Girometti N, Byrne R, Bracchi M, Heskin J, Mcowan A, Tittle V, et al.. Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis. Lancet Infect Dis. 2022. Vol. 22(9):1321–1328

            7. Palich R, Burrel S, Monsel G, Nouchi A, Bleibtreu A, Seang S, et al.. Viral loads in clinical samples of men with monkeypox virus infection: a French case series. Lancet Infect Dis. 2023. Vol. 23:74–80

            8. Colavita F, Antinori A, Nicastri E, Focosi D, Girardi E, Vaia F, et al.. Monkeypox virus in human body sites and fluids: evidence for transmission. Lancet Infect Dis. 2023. Vol. 23:6–8

            9. Thorne LG, Bouhaddou M, Reuschl AK, Zuliani-Alvarez L, Polacco B, Pelin A, et al.. Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature. 2022. Vol. 602(7897):487–495

            10. Shan C, Xia H, Haller SL, Azar SR, Liu Y, Liu J, et al.. A Zika virus envelope mutation preceding the 2015 epidemic enhances virulence and fitness for transmission. Proc Natl Acad Sci U S A. 2020. Vol. 117(33):20190–20197

            11. Isidro J, Borges V, Pinto M, Sobral D, Santos JD, Nunes A, et al.. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med. 2022. Vol. 28(8):1569–1572

            12. Wang L, Shang J, Weng S, Aliyari SR, Ji C, Cheng G, et al.. Genomic annotation and molecular evolution of monkeypox virus outbreak in 2022. J Med Virol. 2022. Vol. 95(1):e28037

            13. Gigante CM, Korber B, Seabolt MH, Wilkins K, Davidson W, Rao AK, et al.. Multiple lineages of monkeypox virus detected in the United States, 2021-2022. Science. 2022. Vol. 378(6619):560–565

            14. Esposito JJ, Sammons SA, Frace AM, Osborne JD, Olsen-Rasmussen M, Zhang M, et al.. Genome sequence diversity and clues to the evolution of variola (smallpox) virus. Science. 2006. Vol. 313(5788):807–812

            15. Mclysaght A, Baldi PF, Gaut BS. Extensive gene gain associated with adaptive evolution of poxviruses. Proc Natl Acad Sci U S A. 2003. Vol. 100(26):15655–15660

            16. Gigante CM, Plumb M, Ruprecht A, Zhao H, Wicker V, Wilkins K, et al.. Genomic deletions and rearrangements in monkeypox virus from the 2022 outbreak, USA. bioRxiv. 2022. 2022–2029. [Cross Ref]

            17. Shchelkunov SN, Totmenin AV, Safronov PF, Mikheev MV, Gutorov VV, Ryazankina OI, et al.. Analysis of the monkeypox virus genome. Virology. 2002. Vol. 297(2):172–194

            18. Matía A, Lorenzo MM, Blasco R. Tools for the targeted genetic modification of poxvirus genomes. Curr Opin Virol. 2020. Vol. 44:183–190

            19. Estep RD, Messaoudi I, O’Connor MA, Li H, Sprague J, Barron A, et al.. Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection. J Virol. 2011. Vol. 85(18):9527–9542

            20. Huang Y, Mu L, Wang W. Monkeypox: epidemiology, pathogenesis, treatment and prevention. Signal Transduct Target Ther. 2022. Vol. 7(1):373

            21. Sherwat A, Brooks JT, Birnkrant D, Kim P. Tecovirimat and the treatment of Monkeypox - past, present, and future considerations. N Engl J Med. 2022. Vol. 387(7):579–581

            22. Khani E, Afsharirad B, Entezari-Maleki T. Monkeypox treatment: current evidence and future perspectives. J Med Virol. 2022. Vol. 95(1):e28229

            23. Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Prevention and treatment of Monkeypox. Drugs. 2022. Vol. 82(9):957–963

            24. Zaeck LM, Lamers MM, Verstrepen BE, Bestebroer TM, van Royen ME, Götz H, et al.. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat Med. 2022. [Cross Ref]

            Author and article information

            Compuscript (Shannon, Ireland )
            11 January 2023
            : 3
            : 1
            [1 ]State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS, Beijing 100071, China
            [2 ]Research Unit of Discovery and Tracing of Natural Focus Diseases, Chinese Academy of Medical Sciences, Beijing 650018, China
            Author notes
            *Corresponding author: E-mail: qincf@ 123456bmi.ac.cn (C-FQ)

            Edited by: Wanbo Tai, The Institute of Infectious Diseases, Shenzhen Bay Laboratory, China

            Reviewed by: Three reviewers who chose to be anonymous

            #These authors contributed equally: Meng-Xu Sun, Xing-Yao Huang.

            Copyright © 2023 The Authors.

            This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

            Page count
            Figures: 1, References: 24, Pages: 4
            Self URI (journal page): https://zoonoses-journal.org/
            Funded by: National Science Fund for Distinguished Young Scholar
            Award ID: 81925025
            Funded by: Innovative Research Group
            Award ID: 81621005
            Funded by: NSFC, and the Innovation Fund for Medical Sciences
            Award ID: 2019-I2M-5-049
            Research in Dr. Cheng-Feng Qin’s laboratory was supported by the National Science Fund for Distinguished Young Scholar (No. 81925025), the Innovative Research Group (No. 81621005) from the NSFC, and the Innovation Fund for Medical Sciences (No.2019-I2M-5-049) from the Chinese Academy of Medical Sciences.

            Parasitology,Animal science & Zoology,Molecular biology,Public health,Microbiology & Virology,Infectious disease & Microbiology


            Comment on this article